vs
Arcellx, Inc.（ACLX）与安进（AMGN）财务数据对比。点击上方公司名可切换其他公司
安进的季度营收约是Arcellx, Inc.的5964.9倍（$9.9B vs $1.7M）。安进净利率更高（13.5% vs -3513.4%，领先3526.9%）。安进同比增速更快（8.6% vs -89.2%）。安进自由现金流更多（$961.0M vs $-58.9M）。过去两年安进的营收复合增速更高（15.1% vs -79.5%）
Arcellx, Inc.是一家处于临床阶段的生物技术企业，专注开发用于治疗血液恶性肿瘤、实体瘤等难治性癌症的CAR-T细胞疗法，其核心管线针对肿瘤领域未被满足的医疗需求，服务全球患者群体。
安进是总部位于美国加利福尼亚州千橡市的跨国生物制药企业，公司名称取自最初的全称「应用分子遗传学」的缩写组合，按营收规模排名位列全球生物医药企业第18位，专注于研发、生产及商业化创新生物药物，为全球患者提供优质治疗选择。
ACLX vs AMGN — 直观对比
营收规模更大
AMGN
是对方的5964.9倍
$1.7M
营收增速更快
AMGN
高出97.8%
-89.2%
净利率更高
AMGN
高出3526.9%
-3513.4%
自由现金流更多
AMGN
多$1.0B
$-58.9M
两年增速更快
AMGN
近两年复合增速
-79.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.7M | $9.9B |
| 净利润 | $-58.1M | $1.3B |
| 毛利率 | — | 69.8% |
| 营业利润率 | -3850.2% | 27.6% |
| 净利率 | -3513.4% | 13.5% |
| 营收同比 | -89.2% | 8.6% |
| 净利润同比 | -23.4% | 112.6% |
| 每股收益（稀释后） | $-1.01 | $2.45 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACLXAMGN
| Q4 25 | $1.7M | $9.9B | ||
| Q3 25 | $4.9M | $9.6B | ||
| Q2 25 | $7.6M | $9.2B | ||
| Q1 25 | $8.1M | $8.1B | ||
| Q4 24 | $15.3M | $9.1B | ||
| Q3 24 | $26.0M | $8.5B | ||
| Q2 24 | $27.4M | $8.4B | ||
| Q1 24 | $39.3M | $7.4B |
净利润ACLXAMGN
| Q4 25 | $-58.1M | $1.3B | ||
| Q3 25 | $-55.8M | $3.2B | ||
| Q2 25 | $-52.8M | $1.4B | ||
| Q1 25 | $-62.3M | $1.7B | ||
| Q4 24 | $-47.1M | $627.0M | ||
| Q3 24 | $-25.9M | $2.8B | ||
| Q2 24 | $-27.2M | $746.0M | ||
| Q1 24 | $-7.2M | $-113.0M |
毛利率ACLXAMGN
| Q4 25 | — | 69.8% | ||
| Q3 25 | — | 67.8% | ||
| Q2 25 | — | 67.2% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 65.7% | ||
| Q3 24 | — | 61.1% | ||
| Q2 24 | — | 61.4% | ||
| Q1 24 | — | 57.0% |
营业利润率ACLXAMGN
| Q4 25 | -3850.2% | 27.6% | ||
| Q3 25 | -1248.3% | 26.4% | ||
| Q2 25 | -777.4% | 28.9% | ||
| Q1 25 | -847.6% | 14.5% | ||
| Q4 24 | -348.2% | 25.4% | ||
| Q3 24 | -129.1% | 24.1% | ||
| Q2 24 | -127.8% | 22.8% | ||
| Q1 24 | -40.3% | 13.3% |
净利率ACLXAMGN
| Q4 25 | -3513.4% | 13.5% | ||
| Q3 25 | -1127.1% | 33.7% | ||
| Q2 25 | -698.6% | 15.6% | ||
| Q1 25 | -766.0% | 21.2% | ||
| Q4 24 | -308.4% | 6.9% | ||
| Q3 24 | -99.4% | 33.3% | ||
| Q2 24 | -99.3% | 8.9% | ||
| Q1 24 | -18.3% | -1.5% |
每股收益（稀释后）ACLXAMGN
| Q4 25 | $-1.01 | $2.45 | ||
| Q3 25 | $-0.99 | $5.93 | ||
| Q2 25 | $-0.94 | $2.65 | ||
| Q1 25 | $-1.13 | $3.20 | ||
| Q4 24 | $-0.87 | $1.17 | ||
| Q3 24 | $-0.48 | $5.22 | ||
| Q2 24 | $-0.51 | $1.38 | ||
| Q1 24 | $-0.14 | $-0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $450.3M | $9.1B |
| 总债务越低越好 | — | $54.6B |
| 股东权益账面价值 | $402.4M | $8.7B |
| 总资产 | $604.0M | $90.6B |
| 负债/权益比越低杠杆越低 | — | 6.31× |
8季度趋势，按日历期对齐
现金及短期投资ACLXAMGN
| Q4 25 | $450.3M | $9.1B | ||
| Q3 25 | $461.4M | $9.4B | ||
| Q2 25 | $453.1M | $8.0B | ||
| Q1 25 | $543.3M | $8.8B | ||
| Q4 24 | $587.4M | $12.0B | ||
| Q3 24 | $574.3M | $9.0B | ||
| Q2 24 | $516.7M | $9.3B | ||
| Q1 24 | $573.9M | $9.7B |
总债务ACLXAMGN
| Q4 25 | — | $54.6B | ||
| Q3 25 | — | $54.6B | ||
| Q2 25 | — | $56.2B | ||
| Q1 25 | — | $57.4B | ||
| Q4 24 | — | $60.1B | ||
| Q3 24 | — | $60.4B | ||
| Q2 24 | — | $62.6B | ||
| Q1 24 | — | $64.0B |
股东权益ACLXAMGN
| Q4 25 | $402.4M | $8.7B | ||
| Q3 25 | $440.8M | $9.6B | ||
| Q2 25 | $392.2M | $7.4B | ||
| Q1 25 | $416.9M | $6.2B | ||
| Q4 24 | $454.8M | $5.9B | ||
| Q3 24 | $483.0M | $7.5B | ||
| Q2 24 | $487.2M | $5.9B | ||
| Q1 24 | $496.6M | $5.0B |
总资产ACLXAMGN
| Q4 25 | $604.0M | $90.6B | ||
| Q3 25 | $655.9M | $90.1B | ||
| Q2 25 | $619.1M | $87.9B | ||
| Q1 25 | $648.1M | $89.4B | ||
| Q4 24 | $711.3M | $91.8B | ||
| Q3 24 | $764.9M | $90.9B | ||
| Q2 24 | $734.3M | $90.9B | ||
| Q1 24 | $779.7M | $93.0B |
负债/权益比ACLXAMGN
| Q4 25 | — | 6.31× | ||
| Q3 25 | — | 5.67× | ||
| Q2 25 | — | 7.57× | ||
| Q1 25 | — | 9.24× | ||
| Q4 24 | — | 10.23× | ||
| Q3 24 | — | 8.02× | ||
| Q2 24 | — | 10.57× | ||
| Q1 24 | — | 12.75× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-58.2M | $1.6B |
| 自由现金流经营现金流 - 资本支出 | $-58.9M | $961.0M |
| 自由现金流率自由现金流/营收 | -3563.4% | 9.7% |
| 资本支出强度资本支出/营收 | 46.2% | 6.5% |
| 现金转化率经营现金流/净利润 | — | 1.20× |
| 过去12个月自由现金流最近4个季度 | $-212.6M | $8.1B |
8季度趋势，按日历期对齐
经营现金流ACLXAMGN
| Q4 25 | $-58.2M | $1.6B | ||
| Q3 25 | $-49.2M | $4.7B | ||
| Q2 25 | $-39.7M | $2.3B | ||
| Q1 25 | $-63.1M | $1.4B | ||
| Q4 24 | $-46.0M | $4.8B | ||
| Q3 24 | $30.7M | $3.6B | ||
| Q2 24 | $-36.2M | $2.5B | ||
| Q1 24 | $-31.9M | $689.0M |
自由现金流ACLXAMGN
| Q4 25 | $-58.9M | $961.0M | ||
| Q3 25 | $-49.5M | $4.2B | ||
| Q2 25 | $-40.2M | $1.9B | ||
| Q1 25 | $-63.9M | $980.0M | ||
| Q4 24 | $-47.5M | $4.4B | ||
| Q3 24 | $28.4M | $3.3B | ||
| Q2 24 | $-39.5M | $2.2B | ||
| Q1 24 | $-38.3M | $459.0M |
自由现金流率ACLXAMGN
| Q4 25 | -3563.4% | 9.7% | ||
| Q3 25 | -1000.3% | 44.4% | ||
| Q2 25 | -532.4% | 20.8% | ||
| Q1 25 | -786.4% | 12.0% | ||
| Q4 24 | -311.3% | 48.4% | ||
| Q3 24 | 109.2% | 39.0% | ||
| Q2 24 | -144.1% | 26.5% | ||
| Q1 24 | -97.7% | 6.2% |
资本支出强度ACLXAMGN
| Q4 25 | 46.2% | 6.5% | ||
| Q3 25 | 6.0% | 4.6% | ||
| Q2 25 | 6.4% | 4.0% | ||
| Q1 25 | 9.6% | 5.0% | ||
| Q4 24 | 9.8% | 4.1% | ||
| Q3 24 | 8.8% | 3.0% | ||
| Q2 24 | 11.7% | 2.8% | ||
| Q1 24 | 16.4% | 3.1% |
现金转化率ACLXAMGN
| Q4 25 | — | 1.20× | ||
| Q3 25 | — | 1.46× | ||
| Q2 25 | — | 1.59× | ||
| Q1 25 | — | 0.80× | ||
| Q4 24 | — | 7.61× | ||
| Q3 24 | — | 1.26× | ||
| Q2 24 | — | 3.30× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACLX
暂无分部数据
AMGN
| Products | $9.4B | 95% |
| Xgeva | $291.0M | 3% |
| Vectibix | $163.0M | 2% |
| Aranesp | $115.0M | 1% |
